Targets › KLK2
2 programs from 1 company in 5 trials: 5 Phase 1; Oncology; next expected readout Dec 2026.
Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin. (UniProt, P20151)
Open in Phaseline: the race on KLK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Johnson & Johnson (Janssen) | JNJ-69086420 Actinium-225-labeled anti-hK2 antibody (alpha-particle emitting radiopharmaceutical) | KLK2 | Phase 1 | Prostatic Neoplasms | Dec 2026 |
| Johnson & Johnson (Janssen) | JNJ-78278343 KLK2-CD3 bispecific antibody (pasritamig) | KLK2, CD3E | Phase 1 | Prostatic Neoplasms | Dec 2026 |
Prostatic Neoplasms (5)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.